PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression (Q81241499)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851564%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

title

PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851564%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

3

J H Beijnen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851564%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

A S Zandvliet

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851564%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

W S Siegel-Lakhai

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851564%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

W Copalu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851564%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

M-C Etienne-Grimaldi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851564%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

G Milano

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851564%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

J H M Schellens

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851564%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

A D R Huitema

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851564%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

publication date

12 September 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851564%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

7 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851564%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

83

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851564%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851564%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

829-839

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851564%20AND%20SRC:MED&resulttype=core&format=json

Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle

7 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100344

7 January 2021

Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100344

7 January 2021

Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100344

7 January 2021

Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100344

7 January 2021

Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100344

7 January 2021

Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100344

7 January 2021

A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100344

7 January 2021

A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100344

7 January 2021

Phase II study of E7070 in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100344

7 January 2021

An adverse interaction between warfarin and 5-fluorouracil: A case report and review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100344

7 January 2021

An adverse interaction between warfarin and capecitabine: a case report and review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100344

7 January 2021

Warfarin-5-FU interaction--a consecutive case series

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100344

7 January 2021

Inhibitory effect of 5-fluorouracil on human cytochrome P(450) isoforms in human liver microsomes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100344

7 January 2021

The evolution of fluoropyrimidine therapy: from intravenous to oral

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100344

7 January 2021

Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100344

7 January 2021

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100344

7 January 2021

Model of chemotherapy-induced myelosuppression with parameter consistency across drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100344

7 January 2021

Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100344

7 January 2021

Depression of phenytoin metabolic capacity by 5-fluorouracil and doxifluridine in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100344

7 January 2021

CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100344

7 January 2021

Effect of 5-fluorouracil on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100344

7 January 2021

Phenytoin and fluorouracil interaction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100344

7 January 2021

A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100344

7 January 2021

Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100344

7 January 2021

Diagnosing model diagnostics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100344

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100344

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17851564%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference